Collaborative Research and Development Agreements (Additional Information) (Details) - Collaborative Arrangement [Member] - Centessa Pharmaceuticals (UK) Limited (Centessa) [Member] - USD ($) $ in Millions |
Nov. 24, 2023 |
Jun. 30, 2026 |
|---|---|---|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||
| Potential future payments | $ 10.0 | $ 10.0 |
| License Agreement, Centessa Pharmaceuticals (UK) Limited [Member] | ||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||
| Reimbursement | 3.0 | |
| Front cash payment | 4.0 | |
| Transaction costs incurred | 0.3 | |
| Total transaction | $ 7.3 |
| X | ||||||||||
- Definition Asset Acquisition, Contingent Consideration Arrangements, Range of Outcomes, Value, High No definition available.
|
| X | ||||||||||
- Definition Reimbursement Payments to Acquire Productive Assets No definition available.
|
| X | ||||||||||
- Definition Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of transaction cost incurred as part of consideration transferred in asset acquisition. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|